Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells

Biochemical and Biophysical Research Communications

Volumn 473, Issue 2, 2016, Pages 490-496

  Matsumoto, Masaru ^a   Nakajima, Wataru ^a   Seike, Masahiro ^a   Gemma, Akihiko ^a   Tanaka, Nobuyuki ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

ABT 263; Apoptosis; Bak; Bax; Cisplatin; NSCLC

Indexed keywords

CISPLATIN; NAVITOCLAX; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL XL; PROTEIN P53; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; SULFONAMIDE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; LUNG; LUNG NEOPLASMS; METABOLISM; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DRUG SYNERGISM; HUMANS; LUNG; LUNG NEOPLASMS; MUTATION; SIGNAL TRANSDUCTION; SULFONAMIDES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84961918696     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.03.053     Document Type: Article

References (36)

1. Z. Chen, C.M. Fillmore, P.S. Hammerman, C.F. Kim, and K.K. Wong Non-small-cell lung cancers: a heterogeneous set of diseases Nat. Rev. Cancer 14 2014 535 546
2. B. Hallberg, and R.H. Palmer Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology Nat. Rev. Cancer 13 2013 685 700
3. W. Pao, and J. Chmielecki Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer Nat. Rev. Cancer 10 2010 760 774
4. V. Boolell, M. Alamgeer, D.N. Watkins, and V. Ganju The Evolution of Therapies Non-small Cell Lung Cancer, Cancers (Basel) vol. 7 2015 1815 1846
5. C.A. Perez, M. Velez, L.E. Raez, and E.S. Santos Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation Lung Cancer 84 2014 110 115
6. D.S. Ettinger, W. Akerley, H. Borghaei, A.C. Chang, R.T. Cheney, L.R. Chirieac, T.A. D'Amico, T.L. Demmy, A.K. Ganti, R. Govindan, F.W. Grannis Jr., L. Horn, T.M. Jahan, M. Jahanzeb, A. Kessinger, R. Komaki, F.M. Kong, M.G. Kris, L.M. Krug, I.T. Lennes, B.W. Loo Jr., R. Martins, J. O'Malley, R.U. Osarogiagbon, G.A. Otterson, J.D. Patel, M.C. Pinder-Schenck, K.M. Pisters, K. Reckamp, G.J. Riely, E. Rohren, S.J. Swanson, D.E. Wood, S.C. Yang, M. Hughes, K.M. Gregory, and NCCN Non-small cell lung cancer J. Natl. Compr. Canc. Netw. 10 2012 1236 1271
7. A. Rossi, P. Chiodini, J.M. Sun, M.E. O'Brien, C. von Plessen, F. Barata, K. Park, S. Popat, B. Bergman, B. Parente, C. Gallo, C. Gridelli, F. Perrone, and M. Di Maio Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data Lancet Oncol. 15 2014 1254 1262
8. S. Dasari, and P.B. Tchounwou Cisplatin in cancer therapy: molecular mechanisms of action Eur. J. Pharmacol. 740 2014 364 378
9. S. O'Grady, S.P. Finn, S. Cuffe, D.J. Richard, K.J. O'Byrne, and M.P. Barr The role of DNA repair pathways in cisplatin resistant lung cancer Cancer Treat. Rev. 40 2014 1161 1170
10. K.H. Vousden, and C. Prives Blinded by the light: the growing complexity of p53 Cell 137 2009 413 431
11. K. Viktorsson, J. Ekedahl, M.C. Lindebro, R. Lewensohn, B. Zhivotovsky, S. Linder, and M.C. Shoshan Defective stress kinase and Bak activation in response to ionizing radiation but not cisplatin in a non-small cell lung carcinoma cell line Exp. Cell Res. 289 2003 256 264
12. P.E. Czabotar, G. Lessene, A. Strasser, and J.M. Adams Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy Nat. Rev. Mol. Cell Biol. 15 2014 49 63
13. R.J. Youle, and A. Strasser The BCL-2 protein family: opposing activities that mediate cell death Nat. Rev. Mol. Cell Biol. 9 2008 47 59
14. H.C. Chen, M. Kanai, A. Inoue-Yamauchi, H.C. Tu, Y. Huang, D. Ren, H. Kim, S. Takeda, D.E. Reyna, P.M. Chan, Y.T. Ganesan, C.P. Liao, E. Gavathiotis, J.J. Hsieh, and E.H. Cheng An interconnected hierarchical model of cell death regulation by the BCL-2 family Nat. Cell Biol. 17 2015 1270 1281
15. I. Kamer, R. Sarig, Y. Zaltsman, H. Niv, G. Oberkovitz, L. Regev, G. Haimovich, Y. Lerenthal, R.C. Marcellus, and A. Gross Proapoptotic BID is an ATM effector in the DNA-damage response Cell 122 2005 593 603
16. K. Nakano, and K.H. Vousden PUMA, a novel proapoptotic gene, is induced by p53 Mol. Cell 7 2001 683 694
17. E. Oda, R. Ohki, H. Murasawa, J. Nemoto, T. Shibue, T. Yamashita, T. Tokino, T. Taniguchi, and N. Tanaka Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis Science 288 2000 1053 1058
18. J. Yu, L. Zhang, P.M. Hwang, K.W. Kinzler, and B. Vogelstein PUMA induces the rapid apoptosis of colorectal cancer cells Mol. Cell 7 2001 673 682
19. S.S. Zinkel, K.E. Hurov, C. Ong, F.M. Abtahi, A. Gross, and S.J. Korsmeyer A role for proapoptotic BID in the DNA-damage response Cell 122 2005 579 591
20. W. Nakajima, M.A. Hicks, N. Tanaka, G.W. Krystal, and H. Harada Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer Cell Death Dis. 5 2014 e1052
21. K. Kawauchi, K. Araki, K. Tobiume, and N. Tanaka p53 regulates glucose metabolism through an IKK-NF-kB pathway and inhibits cell transformation Nat. Cell Biol. 10 2008 611 618
22. A.V. Miller, M.A. Hicks, W. Nakajima, A.C. Richardson, J.J. Windle, and H. Harada Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor PLoS One 8 2013 e60685
23. C. Sheridan, G. Brumatti, M. Elgendy, M. Brunet, and S.J. Martin An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs Oncogene 29 2010 6428 6441
24. M.D. Hall, K.A. Telma, K.E. Chang, T.D. Lee, J.P. Madigan, J.R. Lloyd, I.S. Goldlust, J.D. Hoeschele, and M.M. Gottesman Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes Cancer Res. 74 2014 3913 3922
25. V. Graupner, E. Alexander, T. Overkamp, O. Rothfuss, V. De Laurenzi, B.F. Gillissen, P.T. Daniel, K. Schulze-Osthoff, and F. Essmann Differential regulation of the proapoptotic multidomain protein Bak by p53 and p73 at the promoter level Cell Death Differ. 18 2011 1130 1139
26. C.M. Goodwin, O.W. Rossanese, E.T. Olejniczak, and S.W. Fesik Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer Cell Death Differ. 22 2015 2098 2106
27. H. Zhang, S. Guttikonda, L. Roberts, T. Uziel, D. Semizarov, S.W. Elmore, J.D. Leverson, and L.T. Lam Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines Oncogene 30 2011 1963 1968
28. C. Billard BH3 mimetics: status of the field and new developments Mol. Cancer Ther. 12 2013 1691 1700
29. M.S. Cragg, C. Harris, A. Strasser, and C.L. Scott Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics Nat. Rev. Cancer 9 2009 321 326
30. R.M. Perciavalle, and J.T. Opferman Delving deeper: MCL-1's contributions to normal and cancer biology Trends Cell. Biol. 23 2013 22 29
31. C. Ploner, R. Kofler, and A. Villunger Noxa: at the tip of the balance between life and death Oncogene 27 Suppl. 1 2008 S84 S92
32. M. Hijikata, N. Kato, T. Sato, Y. Kagami, and K. Shimotohno Molecular cloning and characterization of a cDNA for a novel phorbol-12-myristate-13-acetate-responsive gene that is highly expressed in an adult T-cell leukemia cell line J. Virol. 64 1990 4632 4639
33. P. De Feudis, D. Debernardis, P. Beccaglia, M. Valenti, E. Graniela Sire, D. Arzani, S. Stanzione, S. Parodi, M. D'Incalci, P. Russo, and M. Broggini DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status Br. J. Cancer 76 1997 474 479
34. D. Wang, and S.J. Lippard Cellular processing of platinum anticancer drugs Nat. Rev. Drug Discov. 4 2005 307 320
35. M. Stros, T. Ozaki, A. Bacikova, H. Kageyama, and A. Nakagawara HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter J. Biol. Chem. 277 2002 7157 7164
36. W. Nakajima, K. Sharma, M.A. Hicks, N. Le, R. Brown, G.W. Krystal, and H. Harada Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer Cancer Biol. Ther. 17 2016 27 35